|
Net profit up 28%, in line with our forecast As of December 31, 2009, the company's fiscal year 2010 mid-term Sell Revenue and net profit of 6.83 billion Hong Kong dollars and 1.02 billion, year on year increase of 25% and 28%. In July 2009 made for the shares, resulting in the weighted average number of shares over the same period, basic earnings per share increased 1% year on year to 7.7 cents per share, in fiscal year 2010, the company's interim results consistent with our forecast. Beauty skin care business sales 60.1% year on year growth 2010 mid-year, the company's own product turnover of 529 million Hong Kong dollars, up 26.6%. Among them, the traditional gynecological Drugs Sales of about 305 million Hong Kong dollars, representing 45.6% of its own product sales, sales rose by 4.2% year on year; biological pharmaceutical sales of about 7,900 million, representing 11.8% of its own product sales, sales rose 37.4% year on year; beauty care product sales of about 285 million Hong Kong dollars, accounting for 42.6% of its own product sales, sales rose 60.1% year on year. In addition, the company's trading business turnover of 14.3 million Hong Kong dollars. Speed three sales channels to expand, to help fast-growing sales In the first half of fiscal year 2010 to consolidate the existing traditional gynecological hospital pharmaceutical market, with gynecological Zaizao pills-based implementation of direct and portfolio Proxy Parallel forward, and into the national essential drugs catalog of the 31 species actively develop rural areas, communities and other third terminal market. Non-prescription drugs has nearly 70,000 pharmacies to enter sales. Meanwhile, the company has enhanced the biological Pharmacy Pui Yi Fu Yi field sales force of two new drugs, rapid expansion of the hospital channel, into about 2,000 hospitals; company began to develop second and third line of beauty care products market, sales channels, the number of supermarkets, retail outlets have been over 2500. Net profit margin 0.3 percentage points up slightly Mid-fiscal year 2010, the company's gross margin was 57.1%, down just 0.7 percent year on year. Cost of sales percentage of total sales channel expansion by actively promoting increased by 2.9% year on year. Administrative costs account for the proportion of sales revenue fell 3.2%. Benefit from a substantial decline in financing costs decreased 74% and the rate of the company's net profit margin edged up 0.3 percentage points to 15%. Maintain the target price of 2.85 Hong Kong dollars change, maintain Buy rating Company's fiscal year 2010 interim results consistent with our forecast, we maintain profit forecast unchanged, maintaining the company's 12-month target price of 2.85 Hong Kong dollars unchanged target price of the corresponding fiscal year 2010 and fiscal 2011 were forecast price-earnings ratio 15.0 times and 9.5 times the target price higher than current prices are up 19.7% space, we maintain investment grade to buy. We are high quality suppliers, our products such as China passenger vehicles , liquid nitrogen for oversee buyer. To know more, please visits China Products.
Related Articles -
China passenger vehicles, liquid nitrogen,
|
